title: Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis.
abstract: BACKGROUND
  The aim was to evaluate pancreatic exocrine and endocrine function, pancreatic atrophy and main pancreatic duct dilatation in the pancreatic remnant following pancreaticoduodenectomy and pancreaticogastrostomy.
  
  
  METHODS
  Nineteen patients who underwent pancreaticoduodenectomy and pancreaticogastrostomy for benign or malignant pancreatic tumours with a histologically normal pancreatic resection margin were studied prospectively. The median interval between operation and evaluation was 32 (range 12-120) months. Pancreatic exocrine insufficiency was assessed by measuring 72-h faecal fat concentrations and faecal-1 elastase. Fasting blood glucose, haemoglobin A1c, serum peptide C and insulin levels were used to assess endocrine function. Pancreatic parenchymal thickness and main pancreatic duct diameter were measured before operation and at evaluation using computed tomography (CT).
  
  
  RESULTS
  Faecal fat excretion was raised in 16 of 17 patients; faecal-1 elastase was reduced in all 17 patients. None of the 17 non-diabetic patients had developed diabetes mellitus at follow-up. A significant decrease in pancreatic parenchymal thickness and increased dilatation of the main pancreatic duct were observed on CT at evaluation (P = 0.01 and P = 0.01 respectively). Pancreatic atrophy, assessed by subtracting the diameter of the pancreatic duct from the total gland thickness, tended to develop over time, but at the limit of statistical significance (P = 0.06).
  
  
  CONCLUSIONS
  A median of 3 years following pancreaticoduodenectomy and pancreaticogastrostomy, patients remained free from diabetes but developed marked pancreatic exocrine insufficiency. Presented in part to the Societé Nationale Française de Gastroentérologie in Nantes, March 1999, and published in abstract form as Gastroenterol Clin Biol 1999; 23: A81
authors.affiliation: Medico-Surgical Federation of Hepato-Gastroenterology, Beaujon Hospital, Clichy, France.
authors.forename: E
authors.initials: E
authors.lastname: Lemaire
authors.forename: D
authors.initials: D
authors.lastname: O'Toole
authors.forename: A
authors.initials: A
authors.lastname: Sauvanet
authors.forename: P
authors.initials: P
authors.lastname: Hammel
authors.forename: J
authors.initials: J
authors.lastname: Belghiti
authors.forename: P
authors.initials: P
authors.lastname: Ruszniewski
mesh_terms: D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology; D010188:Exocrine Pancreatic Insufficiency / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D005243:Feces / Q000737:chemistry; D005260:Female; D005500:Follow-Up Studies; D005774:Gastrostomy / Q000379:methods*; D018149:Glucose Intolerance / Q000209:etiology; D006801:Humans; D008055:Lipids / Q000032:analysis; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D010183:Pancreatic Ducts / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D016577:Pancreaticoduodenectomy / Q000379:methods*; D011184:Postoperative Period
chemical_list: D008055:Lipids